Sanofi, Maxygen Ink Dengue Virus Vaccine Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.
You may also be interested in...
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial
Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.
Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial
Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.